Ultragenyx reaffirms 2026 total revenue guidance of $730 mln to $760 mln
Company maintains 2026 Crysvita revenue outlook at $500 mln to $520 mln
Ultragenyx expects 2026 combined R&D and SG&A expenses to be flat to slightly down vs 2025
Overview
US biopharma for rare diseases reported Q2 revenue up yr/yr to highest in company history
Net loss for Q2 narrowed yr/yr, with loss per share improving to $0.90 from $1.17
Company reaffirmed 2026 revenue guidance and expects profitability in 2027
Result Drivers
Crysvita sales and royalties - Q2 Crysvita revenue reached $156 mln, with company citing expected seasonality in US/Canada and ordering patterns in Latin America
Evkeeza demand - Q2 Evkeeza revenue was $21 mln, driven by increased demand from new country launches and early access
- Dojolvi launched in Japan in Q2 after approval, contributing to in revenue
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 17 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Ultragenyx Pharmaceutical Inc is $47.50, about 89.8% above its August 3 closing price of $25.02
RARE•
